New

Ketamine May Be Equally Effective in Anxious vs Nonanxious Depression

Researchers found that there is a potential for the use of intravenous ketamine for anxious treatment-resistant depression.

New

FDA: Important Updates to the Clozapine REMS Program

Products covered under the Clozapine REMS program include Clozaril (HLS Therapeutics), Fazaclo (Jazz), and Versacloz (TruPharma), in addition to all generic versions.

New

Smoking Associated With Worsened Symptoms, Quality of Life in Patients With Psychosis

A negative association between number of cigarettes per day and quality of life was observed in patients with psychosis.

New

Insomnia Increases Emotional Dysregulation, Impulsivity, and Suicidality in Bipolar Disorder

Sleep has important functions for the regulation of mood and emotion, and treatment of sleep disturbances in bipolar disorder may improve patient outcomes.

New

NDA Submitted for Novel Insomnia Treatment Lemborexant

The NDA includes data from two Phase 3 clinical trials (SUNRISE 1 and SUNRISE 2) which included approximately 2000 patients.